BMO Capital Reiterates Outperform on Acrivon Therapeutics, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has reiterated its Outperform rating on Acrivon Therapeutics and raised the price target from $25 to $28.

September 16, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has reiterated its Outperform rating on Acrivon Therapeutics and increased the price target from $25 to $28, indicating a positive outlook.
The reiteration of an Outperform rating and an increased price target from a reputable analyst can boost investor confidence and potentially lead to a short-term increase in ACRV's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100